July 1, 2010 - Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon(R) (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules.
Exelon(R) is used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) in people with Alzheimer's disease... Watson Pharmaceuticals' Press Release -
